Pembrolizumab: Opsoclonus myoclonus ataxia syndrome.
In: Reactions Weekly, Jg. 2013 (2024-06-22), Heft 1, S. 346-346
serialPeriodical
Zugriff:
A 72-year-old man developed opsoclonus myoclonus ataxia syndrome (OMAS) while being treated with pembrolizumab for squamous cell carcinoma. He experienced symptoms such as dizziness, shaking, blurred vision, and cognitive decline. Neurological examination revealed opsoclonus, encephalopathy, ataxia, and involuntary muscle contractions. Treatment with prednisolone led to improvement, and the patient was able to regain some independence. This case highlights the potential side effects of pembrolizumab and the importance of monitoring patients for neurological symptoms during treatment. [Extracted from the article]
Titel: |
Pembrolizumab: Opsoclonus myoclonus ataxia syndrome.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 2013 (2024-06-22), Heft 1, S. 346-346 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-024-61360-7 |
Schlagwort: |
|
Sonstiges: |
|